chloroquine has been researched along with Thrombosis in 8 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pandemic outbreak of coronavirus disease 2019 (COVID-19) is rapidly spreading all over the world." | 2.66 | The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. ( Li, T; Liu, Z; Qin, Y; Wang, J; Wang, Q; Yan, X; Zeng, X; Zhang, F; Zhang, S; Zhang, W; Zhang, X; Zhao, Y, 2020) |
| "Patients showed no signs of overt disseminated intravascular coagulation (DIC) in their laboratory analysis." | 1.56 | Severe arterial thromboembolism in patients with Covid-19. ( Buise, MP; Canta, LR; Hendriks, J; Krietemeijer, GM; Lameijer, JRC; Nijziel, MR; Troquay, SAM; van Berckel, MMG; van Houte, J; Yo, LSF, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mendoza-Pinto, C | 1 |
| García-Carrasco, M | 1 |
| Munguía Realpozo, P | 1 |
| Méndez-Martínez, S | 1 |
| Zhang, W | 1 |
| Zhao, Y | 1 |
| Zhang, F | 1 |
| Wang, Q | 1 |
| Li, T | 1 |
| Liu, Z | 1 |
| Wang, J | 1 |
| Qin, Y | 1 |
| Zhang, X | 1 |
| Yan, X | 1 |
| Zeng, X | 1 |
| Zhang, S | 1 |
| Lameijer, JRC | 1 |
| van Houte, J | 1 |
| van Berckel, MMG | 1 |
| Canta, LR | 1 |
| Yo, LSF | 1 |
| Nijziel, MR | 1 |
| Krietemeijer, GM | 1 |
| Troquay, SAM | 1 |
| Buise, MP | 1 |
| Hendriks, J | 1 |
| Anedda, L | 1 |
| Bianchini, L | 1 |
| Cuzzolin, L | 1 |
| Finco, G | 1 |
| Fanos, V | 1 |
| Marcialis, MA | 1 |
| Van Stone, JC | 1 |
| Kovács, IB | 1 |
| Görög, P | 1 |
| Haddock, DR | 1 |
| Bonotey-Ahulu, FI | 1 |
| Janosi, M | 1 |
| Ankra-Badu, G | 1 |
| Reid, HA | 1 |
| Jobin, F | 1 |
| Gagnon, FT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nutritional Habits, Does it Affect Coronavirus Disease 2019 (COVID-19) Infection Outcome? An Egyptian Experience[NCT04447144] | 200 participants (Anticipated) | Observational | 2020-06-01 | Recruiting | |||
| Evaluation of Independent Clinical- Laboratory Predictors of Clinical Outcomes in Hospitalized Positive SARS-CoV2 Patients (Outcomes SARS-CoV2)[NCT05162534] | 1,800 participants (Actual) | Observational | 2020-05-29 | Completed | |||
| Comparison of Cytokine Hemadsorption as an Immunomodulator Therapy in Covid 19 Patients With and Without Bacterial Sepsis[NCT04920851] | 23 participants (Anticipated) | Observational | 2021-06-10 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for chloroquine and Thrombosis
| Article | Year |
|---|---|
Therapeutic options for the management of severe COVID-19: A rheumatology perspective.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; Combined | 2021 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
What if COVID-19 affects the child: which weapons and how to use them.
Topics: Adenosine Monophosphate; Adolescent; Age Factors; Alanine; Antibodies, Monoclonal, Humanized; Antico | 2021 |
1 trial available for chloroquine and Thrombosis
| Article | Year |
|---|---|
Thrombosis in sickle-cell pain crises? Controlled trial of ancrod (Arvin) in young adults.
Topics: Acetaminophen; Adolescent; Adult; Ampicillin; Anemia, Sickle Cell; Child; Chloroquine; Female; Fetal | 1973 |
4 other studies available for chloroquine and Thrombosis
| Article | Year |
|---|---|
Severe arterial thromboembolism in patients with Covid-19.
Topics: Aged, 80 and over; Blood Coagulation; Blood Coagulation Disorders; Chloroquine; COVID-19; COVID-19 D | 2020 |
Hemodialysis and chloroquine poisoning.
Topics: Animals; Chloroquine; Dogs; Dose-Response Relationship, Drug; Inactivation, Metabolic; Poisoning; Re | 1976 |
The effect of anti-inflammatory drugs on the aggregation and adhesiveness of platelets, red cells and leukocytes.
Topics: Adenosine Diphosphate; Aminosalicylic Acids; Animals; Anti-Inflammatory Agents; Antigen-Antibody Com | 1972 |
Platelet reactions and immune processes. IV. The inhibition of complement by pyrazole compounds and other inhibitors of platelet reactions.
Topics: Animals; Blood Coagulation; Blood Platelets; Chloroquine; Complement Inactivator Proteins; Erythrocy | 1970 |